Aytu Therapeutics (AYTU) Enterprise Value to EBITDA Ratio

This price evolution chart on GURU.Markets shows an EV/EBITDA of 0.00, while Aytu BioPharma, Inc. (AYTU) focuses on the internal refinement of ADHD medications and the restructuring of credit obligations. Stable cash flow is supported by sustained demand for prescription drugs. Due to a lack of alternatives in the narrow pediatric medicine segment, Aytu BioPharma, Inc. (AYTU) maintains pricing power over insurers.

Aytu BioPharma - AYTU Company Value to EBITDA (period 11/23/2025 - 11/13/2026)

Comprehensive metric breakdowns and analytics for aytubio.com (AYTU)

- current price and projected stock value:

Stock Price Aytu BioPharma|AYTU - Analyst Median Target

- market capitalization details:

Market Valuation AYTU|AYTU - Full Business Value

- business book valuation details:

Book Value per Share Aytu BioPharma|AYTU - Total Stockholders' Equity|Market Capitalization to Book Value Ratio aytubio.com|AYTU - Total Business Assets

- debt burden and liquidity indicators:

- financial results and valuation multiples details:

AYTU - Final Profit|Expected Profit Aytu BioPharma, Inc.|AYTU - Price to Earnings Ratio|Forward P/E Multiple Aytu BioPharma|AYTU - PEG Multiple|EV/EBITDA Multiple AYTU|AYTU - Operating profit EBITDA|Net earnings per share for the last 12 months Aytu BioPharma|AYTU - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months aytubio.com|AYTU - Net earnings per one share growth for the current year|Expected earnings per share growth for next year Aytu BioPharma, Inc.

Fundamental valuation:Aytu Therapeutics AYTU

For an objective valuation of Aytu BioPharma, Inc. (AYTU) amid market volatility, analyzing enterprise value relative to EBITDA is critical. The current EV/EBITDA multiple allows for the determination of the actual market discount while accounting for debt load, confirming the financial stability of the specialized drug ecosystem for ADHD and pediatric care.

Key competitors

EV/EBITDA Multiple VRTX (Vertex Pharmaceuticals Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam Corp (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma (BBIO)|BGM (BGM Group Limited) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation COGT (Cogent Corp)|Enterprise Value to EBITDA Ratio XERS (Xeris Biopharma)|KROS (kerostx.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharmaceuticals Inc) - Company Value to Operating Income Before Depreciation Ratio|Kamada Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation FULC (Fulcrum Corp)|ABEO: EV/EBITDA Multiple|Mereo BioPharma Group plc (MREO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Protalix BioTherapeutics, Inc.|PLRX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Applied Therapeutics (APLT)|Enterprise Value to EBITDA Ratio Aileron Therapeutics RNTX|EV/EBITDA Multiple GELS (Gelteq)|EV/EBITDA Multiple Chemomab Therapeutics Ltd CMMB|SRx Health - EV/EBITDA Multiple|PLRZ - EV/EBITDA Multiple|AEZS (zentaris.com) - Enterprise Value to EBITDA Ratio|Company Value to EBITDA Cyclo Therapeutics, Inc (CYTH)|Enterprise Value to EBITDA Ratio INZY|RPHM (reneopharma.com) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio CSCI (COSCIENS Biopharma)